Journals / European Journal of Therapeutics / 2021 / Cilt: 27 - Sayı: 4

Effect of Sugammadex on Coagulation Parameters in Cesarean Section Patients a Prospective Controlled Observational Study

Pages
293–298
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed particularly in patients under thromboprophylaxis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate, for the first time in the literature, the effect of sugammadex in elective C/S patients in terms of hemostatic parameters and postoperative bleeding.
📊
Key Findings & Data:At the end of the surgery, after administration of reversal agent, and at postoperative 30th minute, 1st, and 2nd hours, activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) values were recorded.
💡
Conclusion & Impact:Further studies are needed particularly in patients under thromboprophylaxis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate, for the first time in the literature, the effect of sugammadex in elective C/S patients in terms of hemostatic parameters and postoperative bleeding. Methods: Seventy-six patients enrolled for this observational prospective controlled study. Patients were divided into two groups according to anesthetic reversal agent: sugammadex (group I) vs neostigmin (group II). Intraoperative and postoperative amount of bleeding were recorded. At the end of the surgery, after administration of reversal agent, and at postoperative 30th minute, 1st, and 2nd hours, activated partial thromboplastin time (aPTT), prothrombin time (PT), and international normalized ratio (INR) values were recorded. Postoperative Hct, Hgb, and Plt values at 6th and 24th hours of reversal agent administration were also recorded. Results: Alterations in aPTT, PT, and INR values were similar between the groups (P ¼ .986, .549, .05, respectively). Conclusion: Sugammadex at 2 mg kg 1 in cesarean section patients has a similar effect on coagulation parameters compared to neostigmin. Further studies are needed particularly in patients under thromboprophylaxis.

🔖

Cite This Article

DESTEGÜL, D., KOCAÖZ, F., DESTEGÜL, E. (2022). Effect of Sugammadex on Coagulation Parameters in Cesarean Section Patients a Prospective Controlled Observational Study. European Journal of Therapeutics, Cilt: 27 - Sayı: 4, 293–298. https://ajindex.com/articles/512144

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29:125-130. [CrossRef] 2. Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114:409-414. [CrossRef] 3. O’Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003;17:385-396. [CrossRef] 4. Franchini M. Haemostasis and pregnancy. Thromb Haemost. 2006;95:401-413. [CrossRef] 5. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost. 1984;52:176-182. [CrossRef] 6. Bonnar J. Haemostasis and coagulation disorders in pregnancy. In Bloom AL, Thomas DP (eds.): Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1987: 570-584. 7. Letsky EA. Coagulation Problems during Pregnancy. Vol. 10. Edinburgh: Churchill Livingstone, 1985. 8. Greer IA. Haemostasis and thrombosis in pregnancy. In Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds.): Haemostasis and Thrombosis, 3rd ed. Edinburgh: Churchill Livingstone, 1994: 987- 1015. 9. Kinsella SM, Winton AL, Mushambi MC, et al. Int J Obstet Anesth. 2015;24:356-374. [CrossRef] 10. Plaud B, Debaene B, Donati F, Marty J. Residual paralysis after emergence from anesthesia. Anesthesiology. 2010;112:1013-1022. [CrossRef] 11. Naguib M. Sugammadex: Another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104:575-581. [CrossRef] 12. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695-703. [Cross- Ref] 13. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: Synthesis and structure-activity relationships. J Med Chem. 2002;45:1806-1816. [CrossRef] 14. Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. Br J Anaesth. 2012;108:236-239. [CrossRef] 15. Stouracˇ P, Kosinova´ M, Ba´rtı´kova´ I, et al. Sugammadex for active reversal of neuromuscular blockade induced by rocuronium for cesarean delivery in general anesthesia series of case reports [in Czech]. Anest Intenziv Med. 2013;24:163-168. 16. Pu¨ Hringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in caesarean section patients: A series of seven cases. Br J Anaesth. 2010;10